🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

RIR and the Impact on Clinical Outcomes in Patients Undergoing PCI

Recruitingn/aAges 18 Years - 80 YearsAllUnion Hospital, Tongji Medical College, Huazhong …
NCT05131750 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Coronary heart disease (CAD) is caused by myocardial ischemia, hypoxia or necrosis due to coronary artery stenosis, spasm or obstruction. Although standard drug therapy can greatly improve the prognosis of patients with CAD after percutaneous coronary interventions (PCI), these patients are still at high risk of major adverse cardiovascular events (MACE). At present, the concept of residual inflammation risk (RIR) has aroused widespread concern. RIR is an important independent risk in patients with CAD. Foreign studies indicate that hsCRP ≥ 2mg / L is the definition standard of RIR in CAD. In China, there is no defined value of RIR for patients undergoing PCI, and the incidence of RIR has not been investigated clearly. At the same time, the impact of dynamic changes of hsCRP on MACE in PCI population needs to be further explored. Therefore, in this study, we plan to recruit patients und

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: 1. Participants who understand and sign the informed consent form voluntarily; 2. Age ≥ 18 years old and ≤ 80 years old, regardless of sex; 3. The hospitalized patients with coronary heart disease undergoing PCI; 4. Complete all planned PCI during hospitalization Exclusion Criteria: 1. Patients do not receive standardized treatment according to guidelines after being diagnosed with coronary heart disease; 2. Uncontrolled infectious diseases during the screening period; 3. In the screening stage, patients with immune diseases or immune-related diseases such as systemic lupus erythematosus, asthma, inflammatory bowel disease, gout, malignant tumor and so on; 4. Long-term use of non-steroidal anti-inflammatory drugs, hormones, immunomodulatory and chemotherapeutic drugs during the study period; 5. Surgical or interventional treatment was performed within 3 months before the screening period; 6. Pregnant women, lactating women or women of childbearing age who do not use effective contraceptives; 7. Participated in other clinical trials within 3 months before the screening period; 8. The researchers determined that other conditions in which the patient was not suitable to participate in the clinical trial.
💊

What it tests

  • Not listed
📍

Where

1 site
Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy